[Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib].
Wolf
D
D
Abteilung für Hämatologie und Onkologie, Universitätsklinik für Innere Medizin, Universität Innsbruck. dominik.wolf@uibk.ac.at
Gastl
G
G
Rumpold
H
H
D001549:Benzamides; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D004804:Eosinophils / Q000187:drug effects; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D000068877:Imatinib Mesylate; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000627:therapeutic use*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics; D012074:Remission Induction; D020293:Vasculitis, Central Nervous System / Q000175:diagnosis / Q000209:etiology; D039221:mRNA Cleavage and Polyadenylation Factors / Q000235:genetics
D001549:Benzamides; D004791:Enzyme Inhibitors; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D011505:Protein-Tyrosine Kinases; D020796:Receptor, Platelet-Derived Growth Factor alpha
Komplette Remission eines idiopathischen hypereosinophilen Syndroms unter Imatinib.